SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection

  • T. G. Porter
  • S. G. Griego
  • T. K. Hart
  • D. E. Everitt
  • S. B. Dillon
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 137)


Respiratory syncytial virus (RSV) is a major and highly contagious respiratory pathogen that most people are exposed to within the first year or two of life. It is the dominant cause of severe lower respiratory-tract disease (bronchiolitis and pneumonia) in infants and young children, leading to approximately 100,000 hospitalizations each year in the United States alone (HEILMAN 1990). There are two major antigenically distinct subgroups of RSV, A and B, which can circulate simultaneously and are responsible for predictable winter epidemics each year. In adults and older children, symptoms resemble the common cold and are normally mild and confined to the upper respiratory tract. However, in infants and young children, RSV infection often progresses to the lower respiratory tract, where it can lead to serious respiratory complications requiring hospitalization and, in rare cases, may even result in death. Infants with underlying cardiac or pulmonary disease, and some premature/low-birth-weight infants are at considerably higher risk of more severe disease and increased mortality from RSV infection, and are candidates for prophylactic intervention during the winter months. Although not well studied, immunosuppressed adult populations (the elderly, organ-transplant recipients) are also prone to life-threatening infections.


Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Human Respiratory Syncytial Virus Respiratory Syncytial Virus Season Respiratory Syncytial Virus Neutralize Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adair JR (1992) Engineering antibodies for therapy. Immunological Reviews, No. 130: 5 – 39PubMedCrossRefGoogle Scholar
  2. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al. (1992) Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73: 2225 – 2234PubMedCrossRefGoogle Scholar
  3. Azuma J, Kurimoto T, Tsuji S, et al. (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunotherapy 10: 278 – 285CrossRefGoogle Scholar
  4. Beeler JA, Coelingh K (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63: 2941 – 2950PubMedGoogle Scholar
  5. Collins PL (1994) The molecular biology of respiratory syncytial virus (RSV) of the genus pneumovirus, The Paramyxoviruses, Kingsbury DW (ed), Plenum Press, New York, chapter 4, 103 – 162Google Scholar
  6. Crowe JE, Murphy BR, Chanock RM, Williamson RA, Barbas CF, Burton DR (1994) Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV- infected mice. Proc Natl Acad Sci 91: 1386 – 90PubMedCrossRefGoogle Scholar
  7. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR (1995) Pre-clinical pharmacokinetic evaluation of the respiratory syncytial virus-specific virus-specific reshaped human monoclonal antibody SB 209763. Drug Metabolism and Disposition 23: 1028 – 1036PubMedGoogle Scholar
  8. Dimmock NJ (1993) Neutralization of animal viruses. Curr Top Microbiol Immunol 183: 1 – 149PubMedGoogle Scholar
  9. Everitt DE, Davis CB, Thompson K, Boike SC, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK (1996) The pharmacokinetics, antigenicity and fusion- Inhibition activity of SB 209763, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174: 463 – 469PubMedCrossRefGoogle Scholar
  10. Everitt D, Thompson K, DiCicco R, Davis C, Demuth S, Herzyk DJ, Ilson B, Jorkasky D (1995) Safety, pharmacokinetics, antigenicity & fusion inhibition activity of SB 209763, a reshaped human monoclonal antibody to respiratory syncytial virus. Pediatric Research 37: 173AGoogle Scholar
  11. FDA (1994) Draft points to consider in the manufacture and testing of monoclonal antibody products for human use. Center for Bioligics Evaluation and Research, FDA.Google Scholar
  12. Fujinami RS, Oldstone MBA, Wroblewska Z, Frankel ME, Koprowski H (1983). PNAS 80: 2346 – 2350PubMedCrossRefGoogle Scholar
  13. Groothuis JR, Simoes EAF, Levin M J, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children, The New England Journal of Medicine 329: 1524PubMedCrossRefGoogle Scholar
  14. Groothuis JR (1994) The role of RSV neutralizing antibodies in the treatment and prevention or respiratory syncytial virus infection in high risk children. Antiviral Research 23: 1 – 10PubMedCrossRefGoogle Scholar
  15. Hall CB (1994) Prospects for a Respiratory Syncytial Virus Vaccine. Science 265: 1393 – 1394PubMedCrossRefGoogle Scholar
  16. Heilman CA (1990) From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 161: 402 – 406PubMedCrossRefGoogle Scholar
  17. Hogg G, Rodruiguez W, Groothuis, Mills J, Thompson K, Nichols A, Everitt D, Miller A, Herzyk D, Jorkaskyk D (1996) Pharmacokinetics & Safety of RSHZ19, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus, in RSV Infected Infants. Presented at the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996Google Scholar
  18. Hemming VG, Prince GA, Horswood RL, London WT, Murphy BR, Walsh EE, Fischer GW, Weisman LE, Baron PA, Chanock RM (1985) Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis 152: 1083 – 1087PubMedCrossRefGoogle Scholar
  19. Hemming VG, Prince GA (1992) Respiratory Syncytial Virus: Babies and Antibodies. Infectious Agents and Disease 1: 24 – 32PubMedGoogle Scholar
  20. Henry R, Begent J, Pedley RB (1992) Monoclonal antibody administration: current clinical pharmacokinetic status and future trends. Clin Pharmacokinet 23: 85 – 89CrossRefGoogle Scholar
  21. SB 209763: A Humanized Monoclonal AntibodyGoogle Scholar
  22. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrot RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422 – 434PubMedGoogle Scholar
  23. Lewis AP, Barber KA, Cooper HJ, Sims MJ, Worden J, Crowe JS (1993) Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs. Dev Comp Immunol 17: 549 – 560PubMedCrossRefGoogle Scholar
  24. Mark GE, Padlan EA (1994) Humanization of Monoclonal Antibodies. Handb Exp Pharm 113: 105 – 134Google Scholar
  25. Prince GA, Hemming VG, Horswood RL, Baron PA, Murphy BR, Chanock RM (1990) Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats. J Virol 64: 3091 – 3092PubMedGoogle Scholar
  26. Roberts GD, Johnson WP, Burman S, Anumula K, Carr SA (1995) An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus Mab. Analytical Chemistry 67: 3613 – 3625PubMedCrossRefGoogle Scholar
  27. Russell SJ, Llewelyn MB, Hawkins RE (1992) Principles of antibody therapy. BMJ 305: 1424 – 1429PubMedCrossRefGoogle Scholar
  28. Sequeira LA, Cutler RE (1992) Muromonab CD3 (Orthoclone OKT3): part 2, adverse effects, clinical trials, and therapeutic use. Dial Transplant June, 353 – 368Google Scholar
  29. Shadle PJ, Erickson JC Scott RG, Smith TM (1995) Antibody Purification. US Patent No. 5,429, 746.Google Scholar
  30. Stephens S, Emtage S, Vetterlein, et al. (1994) Clinical experience with CDP571, anengineered anti-TNFa antibody. J Cellular Biochem, Supp D, Supp D: 216Google Scholar
  31. Tandai M, Endo T, Sasaki S, Masuho Y, Kochibe N, Kobata A. (1991) Structural study of the sugar moieties of monoclonal antibodies secreted by human-mouse hybri- doma. Arch. Biochem. Biophys. 291: 339 – 348Google Scholar
  32. Tao M-H, Morrison SL (1989) Studies of aglycosylated mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595 – 2601PubMedGoogle Scholar
  33. Taylor G, Stott EJ, Hughes M, Collins AP (1984) Respiratory syncytial virus infection in mice, Infection and Immunity 43: 649PubMedGoogle Scholar
  34. Taylor G, Furze J, Tempest PR, Bremner P, Carr FJ, Harris WJ (1991) Humanised monoclonal antibody to respiratory syncytial virus. Lancet 337: 1411 – 1412PubMedCrossRefGoogle Scholar
  35. Taylor G, Stott EJ, Furze J, Ford J, Sopp P (1992) Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 73: 22 – 27CrossRefGoogle Scholar
  36. Tempest PR, Brenner P, Lambert M, Taylor G, Furze JM, Car FJ, Harris WJ (1991) Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology 9: 266 – 271PubMedCrossRefGoogle Scholar
  37. Thompson KA, Everitt DE, Chapelsky M, Miller AK, Herzyk DJ, Jorkasky D (1996) Safety, pharmacokinetics and antigenicity of single and repeat IM injections of a reshaped human monoclonal antibody (SB 209763) in healthy volunteers. Clin Pharmacol Ther 59: 144CrossRefGoogle Scholar
  38. Trill JJ, Shatzman AR, Ganguly S (1995) Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6: 553 – 560PubMedCrossRefGoogle Scholar
  39. Walsh E, Schlesinger JJ, Bradriss MW (1984) Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies, Infection and Immunity 43: 756.PubMedGoogle Scholar
  40. Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB (1995) Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatric Research 38: 543 – 550PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • T. G. Porter
  • S. G. Griego
  • T. K. Hart
  • D. E. Everitt
  • S. B. Dillon

There are no affiliations available

Personalised recommendations